198 related articles for article (PubMed ID: 27442375)
1. Antiviral Combination Approach as a Perspective to Combat Enterovirus Infections.
Galabov AS; Nikolova I; Vassileva-Pencheva R; Stoyanova A
Pril (Makedon Akad Nauk Umet Odd Med Nauki); 2015; 36(2):91-9. PubMed ID: 27442375
[TBL] [Abstract][Full Text] [Related]
2. Anti-enteroviral triple combination of viral replication inhibitors: activity against coxsackievirus B1 neuroinfection in mice.
Stoyanova A; Nikolova I; Pürstinger G; Dobrikov G; Dimitrov V; Philipov S; Galabov AS
Antivir Chem Chemother; 2015 Dec; 24(5-6):136-147. PubMed ID: 27815331
[TBL] [Abstract][Full Text] [Related]
3. Effect of consecutive alternating administration (CAA) of a triple anti-enteroviral combination on Coxsackievirus B1 neuroinfection in mice.
Stoyanova A; Nikolova I; Galabov AS
Antiviral Res; 2015 Sep; 121():138-44. PubMed ID: 26196747
[TBL] [Abstract][Full Text] [Related]
4. Avoiding drug-resistance development by novel approach of combining anti-enteroviral substances against coxsackievirus B1 infection in mice.
Vassileva-Pencheva R; Galabov AS
Antiviral Res; 2010 Feb; 85(2):366-72. PubMed ID: 19900482
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness of the Consecutive Alternating Administration Course of a Triple Antiviral Combination in Coxsackievirus B3 Infections in Mice.
Vassileva-Pencheva R; Galabov AS
Drug Res (Stuttg); 2016 Dec; 66(12):639-643. PubMed ID: 27552486
[TBL] [Abstract][Full Text] [Related]
6. Direct-acting antivirals and host-targeting strategies to combat enterovirus infections.
Bauer L; Lyoo H; van der Schaar HM; Strating JR; van Kuppeveld FJ
Curr Opin Virol; 2017 Jun; 24():1-8. PubMed ID: 28411509
[TBL] [Abstract][Full Text] [Related]
7. Effect of Consecutive Alternating Administration of a Triple Combination of Anti-Enteroviral Compounds in Mice Infected with Coxsackievirus B3.
Stoyanova A; Galabov AS
Pathog Dis; 2020 Nov; 78(9):. PubMed ID: 33090201
[TBL] [Abstract][Full Text] [Related]
8. Consecutive alternating administration as an effective anti-coxsackievirus B3 in vivo treatment scheme.
Stoyanova A; Galabov AS
Arch Virol; 2021 Jul; 166(7):1869-1875. PubMed ID: 33877422
[TBL] [Abstract][Full Text] [Related]
9. Effects of double combinations of enterovirus replication inhibitors against Coxsackie B viruses.
Stoyanova A; Galabov AS
Acta Virol; 2021; 65(4):411-419. PubMed ID: 34978843
[TBL] [Abstract][Full Text] [Related]
10. Enteroviruses: Classification, Diseases They Cause, and Approaches to Development of Antiviral Drugs.
Nikonov OS; Chernykh ES; Garber MB; Nikonova EY
Biochemistry (Mosc); 2017 Dec; 82(13):1615-1631. PubMed ID: 29523062
[TBL] [Abstract][Full Text] [Related]
11. Antiviral effect of the combination of enviroxime and disoxaril on coxsackievirus B1 infection.
Nikolaeva L; Galabov AS
Acta Virol; 2000 Apr; 44(2):73-8. PubMed ID: 10989697
[TBL] [Abstract][Full Text] [Related]
12. A new paradigm in viral resistance.
Ruiz A; Russell SJ
Cell Res; 2012 Nov; 22(11):1515-7. PubMed ID: 23033124
[TBL] [Abstract][Full Text] [Related]
13. Antivirals against enteroviruses: a critical review from a public-health perspective.
Benschop KS; van der Avoort HG; Duizer E; Koopmans MP
Antivir Ther; 2015; 20(2):121-30. PubMed ID: 25643052
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and anti-enterovirus activity of new analogues of MDL-860.
Dobrikov GM; Slavchev I; Nikolova I; Stoyanova A; Nikolova N; Mukova L; Nikolova R; Shivachev B; Galabov AS
Bioorg Med Chem Lett; 2017 Oct; 27(19):4540-4543. PubMed ID: 28870395
[TBL] [Abstract][Full Text] [Related]
15. Development of resistance to disoxaril in Coxsackie B1 virus-infected newborn mice.
Nikolova I; Galabov AS
Antiviral Res; 2003 Sep; 60(1):35-40. PubMed ID: 14516919
[TBL] [Abstract][Full Text] [Related]
16. Disoxaril mutants of Coxsackievirus B1: phenotypic characteristics and analysis of the target VP1 gene.
Nikolova I; Galabov AS; Petkova R; Chakarov S; Atanasov B
Z Naturforsch C J Biosci; 2011; 66(11-12):627-36. PubMed ID: 22351989
[TBL] [Abstract][Full Text] [Related]
17. Enterovirus infections in neonates.
Tebruegge M; Curtis N
Semin Fetal Neonatal Med; 2009 Aug; 14(4):222-7. PubMed ID: 19303380
[TBL] [Abstract][Full Text] [Related]
18. The efficacy of viral capsid inhibitors in human enterovirus infection and associated diseases.
Li C; Wang H; Shih SR; Chen TC; Li ML
Curr Med Chem; 2007; 14(8):847-56. PubMed ID: 17430140
[TBL] [Abstract][Full Text] [Related]
19. Enteroviral infections in the pathogenesis of type 1 diabetes: new insights for therapeutic intervention.
Richardson SJ; Morgan NG
Curr Opin Pharmacol; 2018 Dec; 43():11-19. PubMed ID: 30064099
[TBL] [Abstract][Full Text] [Related]
20. The combination of pleconaril, rupintrivir, and remdesivir efficiently inhibits enterovirus infections in vitro, delaying the development of drug-resistant virus variants.
Ianevski A; Frøysa IT; Lysvand H; Calitz C; Smura T; Schjelderup Nilsen HJ; Høyer E; Afset JE; Sridhar A; Wolthers KC; Zusinaite E; Tenson T; Kurg R; Oksenych V; Galabov AS; Stoyanova A; Bjørås M; Kainov DE
Antiviral Res; 2024 Apr; 224():105842. PubMed ID: 38417531
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
